These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25022095)

  • 1. [Vitamin E delays Alzheimer disease progression only slightly].
    Hermann DM
    MMW Fortschr Med; 2014 Jun; 156(11):36. PubMed ID: 25022095
    [No Abstract]   [Full Text] [Related]  

  • 2. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 3. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of acetylcholinesterase inhibitor and vitamin E in Alzheimer disease.
    Bittner DM
    J Clin Psychopharmacol; 2009 Oct; 29(5):511-3. PubMed ID: 19745661
    [No Abstract]   [Full Text] [Related]  

  • 5. Selegiline and vitamin E in Alzheimer's disease.
    Adelman A
    J Fam Pract; 1997 Aug; 45(2):98-100. PubMed ID: 9267360
    [No Abstract]   [Full Text] [Related]  

  • 6. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
    Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ
    Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
    Hellweg R; Wirth Y; Janetzky W; Hartmann S
    Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C
    Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-dementia therapy pays at every stage of the disease. Patients with Alzheimer's disease stay all-day fit longer].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():113. PubMed ID: 14579507
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ask the doctor. In your article on Alzheimer's disease (March, 1999), you mention "high doses of vitamin E" as helpful in slowing the progression of the condition. Specifically, what dose is recommended?
    Nicholson CR
    Harv Womens Health Watch; 1999 May; 6(9):8. PubMed ID: 10198461
    [No Abstract]   [Full Text] [Related]  

  • 14. What we can learn from open-label extensions of randomized clinical trials.
    Cummings JL
    Arch Neurol; 2006 Jan; 63(1):18-9. PubMed ID: 16401732
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
    Doody RS; Geldmacher DS; Farlow MR; Sun Y; Moline M; Mackell J
    Dement Geriatr Cogn Disord; 2012; 33(2-3):164-73. PubMed ID: 22572767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S; Wirth Y; Möbius HJ
    Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
    Jones RW; Bayer A; Inglis F; Barker A; Phul R
    Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.